Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials.

@article{Mitry2004ComparisonOT,
  title={Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials.},
  author={Emmanuel Mitry and Christophe Tournigand and Thierry Andr{\'e} and J. Y. Douillard and Christophe Louvet and David Cunningham and Emmanuelle Magherini and D. Mery-mignard and Aimery de Gramont and Philippe Rougier},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3576}
}
3576 Background: With only one 5FU bolus injection and an increased dose of 5FU by continuous infusion, the simplified LV5FU2 regimen is considered as effective as but less toxic and more convenient than the original LV5FU2 de Gramont regimen [Tournigand ASCO 1998 #1052]. LV5FU2-CPT11 and FOLFIRI are safe and active in the front-line treatment of metastatic colorectal cancer [Douillard Lancet 2000 -V303 trial, Tournigand JCO 2004 -V308 trial]. In both regimens, CPT11 is given at a dose of 180… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Management of advanced colorectal cancer, Part 1.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2013
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND